These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. 7-Nitrobenzofurazan (NBD) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A(3) adenosine receptors. Macchia M; Salvetti F; Bertini S; Di Bussolo V; Gattuso L; Gesi M; Hamdan M; Klotz KN; Laragione T; Lucacchini A; Minutolo F; Nencetti S; Papi C; Tuscano D; Martini C Bioorg Med Chem Lett; 2001 Dec; 11(23):3023-6. PubMed ID: 11714602 [TBL] [Abstract][Full Text] [Related]
25. 2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists. Elzein E; Palle V; Wu Y; Maa T; Zeng D; Zablocki J J Med Chem; 2004 Sep; 47(19):4766-73. PubMed ID: 15341491 [TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of putative agonist-binding modes in the human A1 adenosine receptor. Gutiérrez-de-Terán H; Pastor M; Centeno NB; Aqvist J; Sanz F Chembiochem; 2004 Jun; 5(6):841-9. PubMed ID: 15174168 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells. Kim SJ; Min HY; Chung HJ; Park EJ; Hong JY; Kang YJ; Shin DH; Jeong LS; Lee SK Cancer Lett; 2008 Jun; 264(2):309-15. PubMed ID: 18321638 [TBL] [Abstract][Full Text] [Related]
28. 2,9-disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: synthesis, biochemical and molecular modelling studies. Biagi G; Bianucci AM; Coi A; Costa B; Fabbrini L; Giorgi I; Livi O; Micco I; Pacchini F; Santini E; Leonardi M; Nofal FA; Salerni OL; Scartoni V Bioorg Med Chem; 2005 Aug; 13(15):4679-93. PubMed ID: 15908217 [TBL] [Abstract][Full Text] [Related]
29. The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor. DeNinno MP; Masamune H; Chenard LK; DiRico KJ; Eller C; Etienne JB; Tickner JE; Kennedy SP; Knight DR; Kong J; Oleynek JJ; Tracey WR; Hill RJ Bioorg Med Chem Lett; 2006 May; 16(9):2525-7. PubMed ID: 16464581 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations. Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587 [TBL] [Abstract][Full Text] [Related]
31. Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A(2B) receptor dysfunction. Faria M; Magalhães-Cardoso T; Lafuente-de-Carvalho JM; Correia-de-Sá P J Pharmacol Exp Ther; 2006 Oct; 319(1):405-13. PubMed ID: 16837560 [TBL] [Abstract][Full Text] [Related]
32. Homeostatic action of adenosine A3 and A1 receptor agonists on proliferation of hematopoietic precursor cells. Hofer M; Pospísil M; Znojil V; Holá J; Streitová D; Vacek A Exp Biol Med (Maywood); 2008 Jul; 233(7):897-900. PubMed ID: 18445770 [TBL] [Abstract][Full Text] [Related]
33. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding. Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937 [TBL] [Abstract][Full Text] [Related]
34. Effects of stimulation of adenosine A2A receptors on lipopolysaccharide-induced production of reactive oxygen species by equine neutrophils. Sun WC; Moore JN; Hurley DJ; Vandenplas ML; Murray TF Am J Vet Res; 2007 Jun; 68(6):649-56. PubMed ID: 17542699 [TBL] [Abstract][Full Text] [Related]
35. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype. Roy K; Leonard JT; Sengupta C Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147 [TBL] [Abstract][Full Text] [Related]
36. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. Gao ZG; Ye K; Göblyös A; Ijzerman AP; Jacobson KA BMC Pharmacol; 2008 Dec; 8():20. PubMed ID: 19077268 [TBL] [Abstract][Full Text] [Related]
37. Influence of adenosine receptor agonists on benzodiazepine withdrawal signs in mice. Listos J; Malec D; Fidecka S Eur J Pharmacol; 2005 Oct; 523(1-3):71-8. PubMed ID: 16226742 [TBL] [Abstract][Full Text] [Related]
38. Stimulation of ANP secretion by 2-Cl-IB-MECA through A(3) receptor and CaMKII. Yuan K; Bai GY; Park WH; Kim SZ; Kim SH Peptides; 2008 Dec; 29(12):2216-24. PubMed ID: 18838091 [TBL] [Abstract][Full Text] [Related]
39. Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors. Yates L; Clark JH; Martin TJ; James S; Broadley KJ; Kidd EJ Auton Autacoid Pharmacol; 2006 Apr; 26(2):191-200. PubMed ID: 16553647 [TBL] [Abstract][Full Text] [Related]
40. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives. Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]